NASDAQ: ABOSAcumen Pharmaceuticals Inc Stock
$2.36-0.02 (-0.84%)
Updated Oct 8, 2024
ABOS Price
$2.36
Fair Value Price
$0.79
Market Cap
$141.79M
52 Week Low
$1.81
52 Week High
$5.09
P/E
-2.11x
P/B
0.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$64.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$56M
Beta
1.45
Next Earnings
Nov 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ABOS Overview
Acumen Pharmaceuticals Inc. develops therapies for the treatment of Alzheimer's disease. Acumen's approach targets AbOs, a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The company's lead immunotherapy drug candidate ACU193, is a humanized monoclonal antibody that is in Phase I clinical-stage trials. Acumen Pharmaceuticals was incorporated in 1996 and is headquartered in Charlottesville, VA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABOS ($2.36) is overvalued by 198.75% relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABOS ($2.36) is not significantly undervalued (198.75%) relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABOS due diligence checks available for Premium users.
Be the first to know about important ABOS news, forecast changes, insider trades & much more!
ABOS News
Valuation
ABOS fair value
Fair Value of ABOS stock based on Discounted Cash Flow (DCF)
Price
$2.36
Fair Value
$0.79
Overvalued by
198.75%
ABOS ($2.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABOS ($2.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.11x
Industry
-119.06x
Market
27.24x
ABOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
5.97x
ABOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABOS's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.5M
Profit Margin
0%
ABOS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$288.9M
Liabilities
$45.0M
Debt to equity
0.18
ABOS's short-term assets ($266.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABOS's short-term assets ($266.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.5M
Investing
$37.7M
Financing
-$128.0k
ABOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABOS vs Biotech Stocks
Acumen Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.